American Assets Investment Management Has Upped Banco Bilbao Vizcaya Argenta (BBVA) Holding By $350,416; Shorts at Cellect Biotechnology Limited Ads (APOP) Raised By 24.76%

December 6, 2017 - By Peter Erickson

American Assets Investment Management Llc increased Banco Bilbao Vizcaya Argenta (BBVA) stake by 21.33% reported in 2017Q2 SEC filing. American Assets Investment Management Llc acquired 43,802 shares as Banco Bilbao Vizcaya Argenta (BBVA)’s stock rose 24.59%. The American Assets Investment Management Llc holds 249,202 shares with $2.08 million value, up from 205,400 last quarter. Banco Bilbao Vizcaya Argenta now has $55.59B valuation. The stock decreased 1.48% or $0.12 during the last trading session, reaching $8.34. About 1.86M shares traded. Banco Bilbao Vizcaya Argentaria, S.A. (NYSE:BBVA) has risen 32.54% since December 6, 2016 and is uptrending. It has outperformed by 15.84% the S&P500.

Cellect Biotechnology Limited Ads (NASDAQ:APOP) had an increase of 24.76% in short interest. APOP’s SI was 119,400 shares in December as released by FINRA. Its up 24.76% from 95,700 shares previously. With 147,200 avg volume, 1 days are for Cellect Biotechnology Limited Ads (NASDAQ:APOP)’s short sellers to cover APOP’s short positions. The SI to Cellect Biotechnology Limited Ads’s float is 3.8%. The stock decreased 5.56% or $0.426 during the last trading session, reaching $7.234. About 18,830 shares traded. Cellect Biotechnology Ltd. (NASDAQ:APOP) has 0.00% since December 6, 2016 and is . It has underperformed by 16.70% the S&P500.

American Assets Investment Management Llc decreased Paypal Hldgs Inc stake by 15,000 shares to 85,625 valued at $4.60M in 2017Q2. It also reduced Ishares Tr stake by 375,000 shares and now owns 300,000 shares. General Motors Co (NYSE:GM) was reduced too.

Among 8 analysts covering Banco Bilbao Vizcaya Argentaria (NYSE:BBVA), 2 have Buy rating, 4 Sell and 2 Hold. Therefore 25% are positive. Banco Bilbao Vizcaya Argentaria had 9 analyst reports since December 2, 2015 according to SRatingsIntel. The firm has “Sell” rating given on Friday, February 24 by Societe Generale. The stock of Banco Bilbao Vizcaya Argentaria, S.A. (NYSE:BBVA) earned “Outperform” rating by RBC Capital Markets on Wednesday, October 19. Jefferies initiated the shares of BBVA in report on Friday, September 23 with “Buy” rating. UBS initiated the stock with “Sell” rating in Monday, March 7 report. Bank of America downgraded the shares of BBVA in report on Wednesday, December 2 to “Underperform” rating. The firm has “Sell” rating given on Thursday, November 10 by Citigroup. The stock has “Overweight” rating by JP Morgan on Wednesday, February 15. Barclays Capital upgraded the stock to “Equal-Weight” rating in Tuesday, September 6 report. The stock of Banco Bilbao Vizcaya Argentaria, S.A. (NYSE:BBVA) earned “Hold” rating by Jefferies on Wednesday, November 9.

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. The company has market cap of $43.42 million. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com